ALQGC.PA - Quantum Genomics Société Anonyme
Quantum Genomics Société Anonyme
33 rue Marbeuf
Paris 75008
France
33 1 85 34 77 70
https://www.quantum-genomics.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Dr. Jean-Philippe Milon Ph.D. | CEO, MD & Chairman | 415,82k | S.O. | 1960 |
| Mr. Benoît Gueugnon | Admin. & Financial Director, VP of Fin. and CFO | S.O. | S.O. | S.O. |
| Dr. Bruno Besse | Chief Medical Officer | S.O. | S.O. | S.O. |
| Dr. Sarah Merlen-Boulenger | Head of Regulatory Affairs | S.O. | S.O. | S.O. |
Description
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Quantum Genomics Société Anonyme en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..
